GLP-1s & Obesity


Market Context | August 27th



Insurance | Risk Management


Consulting







Complex Pathway of Dealing Drugs...Legally



Pharmacy Benefits Manager (PBM)




G Gallagher



PBM Landscape

U.S. PBM Market Share: Total Prescription Claims Managed in 2021



<u> </u>	Total Revenue in 2021	Specialty Growth	Traditional Growth	
	\$501 Billion	7.5%	4.5%	

- 60+ different PBMs in the market with the Big Three holding ~80% of market share
- Client satisfaction among Big Three is mixed
- Interest in smaller PBMs is growing, as clients skepticism of the jumbo PBM business model increases

Source: The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, Drug Channels Institute



What is a Formulary?

Managed by the PBM's Pharmacy & Therapeutics Committee

List of drugs that are assigned different tiers that will charge certain copays/coinsurance based on plan design

Rebates are an important aspect of most formularies to manage costs Utilization management are important to manage drug costs



Types of Formularies

Open	Exclusionary	Closed	
 All drugs under covered drug classes are available at different tiers Lower rebates and higher plan costs are typically associated with an open formulary but is the most member friendly option among formulary types 	 All drugs under covered drug classes are available at different tiers, with the exception of certain drugs under highly rebate-able classes If members move to the preferred alternatives, they will pay their member share as usual in order to receive their drugs If members do not want to use the preferred alternative, they can either pay for the full cost of the drug or go through a medical necessity process Although this may not be as member friendly, this approach to managing drug costs is standard in the industry 	 Coverage of drugs are limited per drug class to mostly generics and highly rebate-able drugs Members can go through the medical necessity process for excluded drugs, pay for the full cost of the drugs or move to a covered drug Compared to the open and exclusionary formulary, this is a more tightly managed formulary with narrower drug coverage. Therefore, may not be as member friendly but is generally associated with lowest plan costs 	

- Information related to covered drug classes and does not include benefit exclusions that may occur such as weight loss
 drugs and cosmetic agents. Benefit exclusions will take priority over formulary coverage
- Information is related to drug placement on a formulary only and does not include utilization management, such as step therapy, that would required the use of a preferred drug over another before the non-preferred drug is covered
- Regardless of formulary types, decisions on tier and coverage are reviewed and managed by the PBM's Pharmacy and Therapeutic (P&T) Committee



What are Utilization Management Programs?






Obesity

- Overweight is defined as a body mass index (BMI) of 25 or higher
- Obesity is defined as a BMI of 30 or higher*

[Obesity] is linked to mental health by clinical observations and biological pathways [...] thorough screening for mental health problems in patients with obesity is urgently called for to allow prevention and facilitate adequate treatment.**

*From the CDC: <u>https://www.cdc.gov/healthyweight/effects/index.html</u> **From Nature: <u>https://www.nature.com/articles/s41398-023-02447-w</u>



- High I DI /I ow HDI
- Coronary Heart Disease
 Stroke

Endocrine

- Type 2 Diabetes
- Metabolic Disease

Other Conditions

- Gallbladder disease
- Osteoarthritis
- Sleep Apnea
 - Cance


Mental

- Depression
- Anxiety
- Other mental disorders



Prevalence Trends of Obesity

Louisiana trails only West Virginia in Prevalence of Obesity



CDC data show obesity has climbed year-over-year for decades


Obesity rates are highest among Non-Hispanic Native American and Non-Hispanic Black populations



Current State: Obesity Therapies

Americans more likely to view Ozempic, similar drugs as good weight-loss options for people with obesity than for people without a weight-related condition

Among U.S. adults who have heard of Ozempic, Wegovy and other similar drugs, % who say they are **good options for weight loss** for ...




Note: Based on U.S. adults who have heard of Ozempic, Wegovy and other similar drugs. Respondents who did not give an answer are not shown. Source: Survey of U.S. adults conducted Feb. 7-11, 2024.

"How Americans View Weight-Loss Drugs and Their Potential Impact on Obesity in the U.S."

PEW RESEARCH CENTER





🕒 All 🕒 Employer 🔵 Health Plan

Not shown: 7% of respondents were unsure of the plan's status regarding coverage of weight loss medications. Pharmaceutical Strategies Group. 2023 Trends in Drug Benefit Design Report. Dallas, TX: PSG.

https://www.pewresearch.org/science/2024/02/26/how-americans-view-weight-loss-drugs-and-their-potential-impact-on-obesity-in-the-u-s/





European Markets

Novo Nordisk briefly overtakes LVMH as Europe's most valuable company

By Lucy Raitano and Danilo Masoni

September 1, 2023 11:14 AM CDT · Updated 6 months ago



The Motley Fool

Our Services Investing Basics × Stock Market × Retirement × Personal Finance ×

Eli Lilly is the world's largest healthcare company by market cap, and the 10th most valuable business in the world.

The six most valuable companies in the world by market cap all have one thing in common: each is valued at over \$1 trillion. Five of the six are in the technology business, with the exception being **Saudi Arabian Oil**.

With a market cap of roughly \$592 billion, **Eli Lilly (LLY 1.65%)** is the world's largest healthcare company and the 10th most valuable business in the world.


Indeed, Lilly stock has been on a tear lately. In just the last year, the stock has returned nearly 80% -- about triple the return of the S&P 500.



Obesity Drug Pipeline

GlobalData's Pharmaceutical Intelligence Center

Drug Category	Drug Name	МоА	Company	Company Headquarters	Event Type	Event Date
Novel Agents	APHD-012	Undisclosed	Aphaia Pharma	Switzerland	Phase III results	2H
Novel Agents	S-309309	MGAT2 Inhibitor	Shionogi & Co	Japan	Phase II results	1H
Novel Agents	bimagrumab	ACTR2 Antagonist	Versanis Biopharmaceuti cals	United States	Phase II results	1H
Novel Agents	cagrisema (cagrilinitide + semaglutide)	CALCR/RAMP1/2 /3 Agonist + GLP- 1RA	Novo Nordisk	Denmark	Phase II results	2H
Dual Agonists (non GIPR/GLP- 1R)	dapiglutide	GLP-1/GLP-2 Agonist	Zealand Pharma	Denmark	Phase I/II results	1H
Dual GIPR/GLP- 1R Agonists	VK2735	GIPR/GLP-1R Agonist	Viking Therapeutics	United States	Phase II results	2H





ırance | Risk Management | Consultir